The Impact of Induction Treatment Response on the Prognosis of Pediatric Core Binding Factor-Acute Myeloid Leukemia Patients.
10.19746/j.cnki.issn.1009-2137.2021.01.009
- Author:
Hui-Min ZENG
1
;
Guan-Hua HU
1
;
Ai-Dong LU
1
;
Yue-Ping JIA
1
;
Ying-Xi ZUO
1
;
Jun WU
1
;
Le-Ping ZHANG
2
Author Information
1. Department of Pediatrics, People's Hospital Peking University, Beijing 100044, China.
2. Department of Pediatrics, People's Hospital Peking University, Beijing 100044, China,E-mail：zlppeking@163.com.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Child;
Core Binding Factors;
Disease-Free Survival;
Humans;
Induction Chemotherapy;
Leukemia, Myeloid, Acute/drug therapy*;
Prognosis;
Remission Induction;
Retrospective Studies
- From:
Journal of Experimental Hematology
2021;29(1):56-61
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the impact of induction treatment response on the prognosis of pediatric core binding factor-acute myeloid leukemia (CBF-AML).
METHODS:The result of induce reaction and survival data of 157 pediatric CBF-AML patients in our hospital from September 2008 to December 2018 were retrospectively analyzed．The survival rate of the patients with different degrees of morphological remission after induction chemotherapy was comparative analyzed.
RESULTS:Among the 157 children with CBF-AML, 113 (72.4%) patients achieved morphologic leukemia-free state (MLFS) after the first course of induction chemotherapy, 153 (98.1%) patients achieved MLFS after the second course of induction chemotherapy. The 5-year event-free survival (EFS) rate and 5-year overall survival (OS) rate of patients with non-remission (NR) status after the first course of induction of chemotherapy was significantly lower than the patients achieved MLFS and the patients achieved partial remission (PR). The 5-year EFS rate and 5-year OS rate of the patients with PR status after the second course of induction chemotherapy were lower than the patients achieved MLFS, but the difference was not statistically significant. Multivariable analyze showed that NR after the first course of induction chemotherapy and myeloid sarcoma were the independent risk factors affecting EFS of the patients. There were six patients with NR status after the first course of induction chemotherapy, in which all of them harbored t(8;21), three of them with sex chromosome deletion, two of them with myeloid sarcoma.
CONCLUSION:NR status after the first course of induction chemotherapy was the independent risk factor affecting EFS and OS of CBF-AML patients, it can be taken as an indicator for higher risk stratification. PR status after the first course of induction chemotherapy may not be used as a diagnostic criterion for primary drug resistance.
